Product Information
JULUCA 50-25 MG TABLET is a brand product labeled by ViiV Healthcare Company, priced at $121.8664 per EA under NDC 49702024213. Its NADAC has been published 429 times since Jul 18, 2018.
FDA first approved this application on Nov 21, 2017.
Strength
50; 25 mg/1; mg/1
Manufacturer
ViiV Healthcare CompanyNDC
49702024213
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA210192FDA Approved
11/21/2017
On Market Since
11/21/2017
Pharmacological Classes
Price Statistics
The NADAC for JULUCA 50-25 MG TABLET has been published 429 times since Jul 18, 2018, and over the history we have for it it has risen 47.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $121.8664 per EA |
|---|---|
| All-time high | $121.9492 (May 13, 2026) |
| All-time low | $82.6656 (Jul 18, 2018) |
| 52-week high | $121.9492 |
| 52-week low | $118.1782 |
| Median price | $100.9419 |
| Average price | $102.7574 |
| Largest weekly change | +5.9% (Jan 10, 2024) |
| Weeks tracked | 429 |
| Tracking since | Jul 18, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dolutegravir sodium and rilpivirine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ViiV Healthcare Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dolutegravir sodium and rilpivirine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of JULUCA 50-25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for JULUCA 50-25 MG TABLET, manufactured by ViiV Healthcare Company, is $121.8664 per EA (NDC 49702024213), effective Sep 30, 2026.
How has the price of JULUCA 50-25 MG TABLET changed over time?
Over the history we have for it, the NADAC for JULUCA 50-25 MG TABLET has risen 47.4%. It has been tracked across 429 weekly CMS publications since Jul 18, 2018.
What are the highest and lowest recorded NADAC prices for JULUCA 50-25 MG TABLET?
Since Jul 18, 2018, the NADAC for JULUCA 50-25 MG TABLET has ranged from a low of $82.6656 (Jul 18, 2018) to a high of $121.9492 (May 13, 2026), with a median of $100.9419 per EA.
Are there cheaper alternatives to JULUCA 50-25 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of JULUCA 50-25 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures JULUCA 50-25 MG TABLET?
JULUCA 50-25 MG TABLET (NDC 49702024213) is labeled by ViiV Healthcare Company, and CMS classifies it as a brand product.